FLEX Shows Erbitux Strength In NSCLC, CRYSTAL Offers KRAS Biomarker
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With positive results of the Phase III FLEX study in hand - showing an overall survival benefit for Erbitux in first-line non-small cell lung cancer - Bristol-Myers Squibb and partner ImClone are discussing with FDA their plans to use the data as the basis of a supplemental BLA filing, Bristol said in an interview